Tags
- 24 Weeks
- A
- Adult
- Adverse
- Adverse event
- Adverse Events
- Ae
- AES
- Agonist
- Anorexia
- Appetite
- Baseline
- Blinded experiment
- Blood
- Blood pressure
- Blood sugar
- BMI
- Body
- Chinese
- Circumference
- Clinical
- Clinical endpoint
- Clinical trial
- Comparison
- Comparisons
- Conclusion
- Confidence interval
- D
- Data
- Development
- Diabetes
- Diabetes management
- Diarrhea
- Disclosure
- Dose
- Drug development
- Dual
- Efficacy
- Employment
- End-of-life
- Endpoint
- Escalation
- GIP
- Glucagon-like peptide-1
- Glucose
- Glycemic
- Group action
- H
- Human body weight
- Injection
- In-phase and quadrature components
- Introduction
- Jiangsu
- L
- Least squares
- Levels
- Limited company
- Loss
- Lowering
- LTD
- M
- Methods
- MG 30
- MG 45
- Millimeter of mercury
- Moderate
- Most
- Nausea
- No
- Normal distribution
- Novel
- Obesity
- Participation
- Percentage
- Pharmaceutical drug
- Pharmacovigilance
- Phase
- Phase 1
- Phase 1 trials
- PHASE 2
- Phase 2 trial
- Phases of clinical research
- Placebo
- Placebo-controlled study
- Pressure
- Primary
- Profile
- Prominence
- Proportion
- Randomness
- Ranged weapon
- Receptor
- Reducing
- Reduction
- Relative change and difference
- Safety
- Severity
- Shown
- Subcutaneous
- Subcutaneous injection
- Sun
- Systole
- The Waist
- Trial
- Trials
- Triglyceride
- Vomiting
- W24
- Waist
- Weight
- Weight loss
- Zuo